TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31590637

Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI) score 3-4
Number of subjects: 124721

Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI) score 5-6
Number of subjects: 124721

Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI) score > 6
Number of subjects: 124721

Group type: COMPARATOR
Intervention: No comorbidity (CCI = 2)
Number of subjects: 124721
Study: 28555092

Group type: EXPERIMENTAL
Intervention: Tetrodotoxin (TTX) 30 μg subcutaneously twice daily for four consecutive days
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo subcutaneously twice daily for four consecutive days
Number of subjects: 165
Study: 25296741

Group type: EXPERIMENTAL
Intervention: High Velocity Low Amplitude (HVLA) manipulation
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Posteroanterior mobilization (PA mob)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sustain Apophyseal Natural Glide (SNAG)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cervical Range of Motion (CROM)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: VAS in Flexion/Extension
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CROM in Lateral-Flexion movement
Number of subjects: 48
Study: 23118007

Group type: EXPERIMENTAL
Intervention: Patients with depressed heart rate variability (HRV) (≤6.5%)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Patients with bundle branch block (BBB) and large QRS dispersion (>39 ms)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Patients without BBB with reduced maximum T-wave amplitude (<0.4 mV)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: History of atrial arrhythmia
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Secondary prevention
Number of subjects: 108
Study: 21646935

Group type: EXPERIMENTAL
Intervention: Vestipitant
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vestipitant and Paroxetine combination
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 17614015

Group type: EXPERIMENTAL
Intervention: Exercise training (walking and light weight lifting for one hour, 3 times/week)
Number of subjects: 213
Study: 17070157

Group type: EXPERIMENTAL
Intervention: Probucol (1 g/d)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 14628586

Group type: EXPERIMENTAL
Intervention: Acupuncture (AC) combined with drug therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Combined drug therapy
Number of subjects: 90
Study: 10902986

Group type: EXPERIMENTAL
Intervention: E = 1171 kJ + 12 mg iron
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: M = 209 kJ + 12 mg iron
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: S = 104 kJ
Number of subjects: 136
Study: 9552817

Group type: EXPERIMENTAL
Intervention: Miconazole lacquer applied on upper denture base on days 0, 7, and 14
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Miconazole lacquer
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (15 denture wearers)
Number of subjects: 21
Study: 1304210

Group type: EXPERIMENTAL
Intervention: HEMA posterior chamber lens implanted through a 3.5 mm scleral tunnel incision
Number of subjects: 70

Group type: COMPARATOR
Intervention: PMMA posterior chamber lens implanted through a 7 mm scleral step incision
Number of subjects: 70
Study: 3885982

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Althesin
Number of subjects: 0
Study: 31313093

Group type: EXPERIMENTAL
Intervention: HITSystem (eHealth intervention)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control (standard EID services)
Number of subjects: 137
Study: 30057233

Group type: EXPERIMENTAL
Intervention: MAVIG lead shield
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: RADPAD shield
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (no shield)
Number of subjects: 125
Study: 26809601

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Physical Therapy
Number of subjects: 99

Group type: COMPARATOR
Intervention: Enhanced Usual Care
Number of subjects: 99
Study: 24028708

Group type: EXPERIMENTAL
Intervention: Low calcium dialysate (1.25 mmol/L)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard calcium dialysate (1.75 mmol/L)
Number of subjects: 40
Study: 22376791

Group type: EXPERIMENTAL
Intervention: Rest therapy for 10 weeks with a recommendation to rest for two hours daily and the option of using a flexible lumbar belt
Number of subjects: 100

Group type: COMPARATOR
Intervention: Exercise therapy once a week for 10 weeks
Number of subjects: 100
Study: 20888994

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (fludarabine, cyclophosphamide, and rituximab)
Number of subjects: 817

Group type: COMPARATOR
Intervention: Chemotherapy (fludarabine and cyclophosphamide)
Number of subjects: 817
Study: 18391846

Group type: EXPERIMENTAL
Intervention: Indomethacin treatment for 3 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 16
Study: 15920216

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crossover design (substituting anesthetics)
Number of subjects: 0
Study: 11964956

Group type: EXPERIMENTAL
Intervention: 0.4 g/dL oligosaccharides
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.8 g/dL oligosaccharides
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 90
Study: 10214007

Group type: EXPERIMENTAL
Intervention: Epidural block only during operations (group M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion for 2 postoperative days (group B 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion for 4 postoperative days (group B 4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (group M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison of verbal descriptor pain score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abdominal pain after catheter removal
Number of subjects: 0
Study: 7888887

Group type: EXPERIMENTAL
Intervention: Algorithm and instant developing camera
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intervention city
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control city
Number of subjects: 50
Study: 2211560

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: COMPARATOR
Intervention: Trimipramine
Number of subjects: 6
Study: 45210

Group type: EXPERIMENTAL
Intervention: 200 micrograms oxitropium bromide
Number of subjects: 19

Group type: COMPARATOR
Intervention: 40 micrograms ipratropium bromide
Number of subjects: 19

Group type: COMPARATOR
Intervention: 400 micrograms fenoterol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 29510745

Group type: EXPERIMENTAL
Intervention: Autologous dendritic cell vaccines (DCV) with 500 micrograms of GM-CSF, injected weekly for 3 weeks, then at weeks 8, 12, 16, 20, and 24.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Autologous tumor cell vaccines (TCV) with 500 micrograms of GM-CSF, injected weekly for 3 weeks, then at weeks 8, 12, 16, 20, and 24.
Number of subjects: 42
Study: 26828571

Group type: EXPERIMENTAL
Intervention: Cognitive training plus work therapy (n = 15)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Work therapy alone (n = 16)
Number of subjects: 31
Study: 24649895

Group type: EXPERIMENTAL
Intervention: Additional telephone counseling session performed by psychosocial workers
Number of subjects: 264

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 264
Study: 22734829

Group type: EXPERIMENTAL
Intervention: Sevoflurane (vaporiser-dial setting, 1.5%) during one-lung ventilation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sevoflurane (vaporiser-dial setting, 1.5%) during two-lung ventilation
Number of subjects: 8
Study: 21246573

Group type: EXPERIMENTAL
Intervention: 607-nm pulsed dye laser
Number of subjects: 10

Group type: COMPARATOR
Intervention: 595-nm pulsed dye laser
Number of subjects: 10
Study: 17080447

Group type: EXPERIMENTAL
Intervention: 8-week internet-based prevention program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 100
Study: 16307621

Group type: EXPERIMENTAL
Intervention: Educational multimedia computer program
Number of subjects: 194

Group type: COMPARATOR
Intervention: Usual nurse counseling
Number of subjects: 194
Study: 11896508

Group type: EXPERIMENTAL
Intervention: Amlodipine (A)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Benazepril (B)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Amlodipine + Benazepril (A+B)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (A alone)
Number of subjects: 27
Study: 9670386

Group type: EXPERIMENTAL
Intervention: Zancolli classification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASIA motor score
Number of subjects: 0
Study: 7851108

Group type: EXPERIMENTAL
Intervention: Experimental treatment E
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment S
Number of subjects: 0
Study: 3132551

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.10 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.20 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29580209

Group type: EXPERIMENTAL
Intervention: Upper limb muscle strength
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Number of steps taken per day
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Upper limb muscle strength (assistive device users)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Lower limb muscle strength (non-assistive device users)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Time spent in light physical activity (non-assistive device users)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Number of steps walked per day (non-assistive device users)
Number of subjects: 114
Study: 28235809

Group type: EXPERIMENTAL
Intervention: Stent implantation in patients with plaque rupture (n=79)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Stent implantation in patients with plaque erosion (n=62)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Post-stent OCT findings in plaque rupture group
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Cardiac event rates at 1-year follow-up for plaque rupture and erosion groups
Number of subjects: 141
Study: 25640664

Group type: EXPERIMENTAL
Intervention: Prednisolone (50 mg for 10 days)
Number of subjects: 55
Study: 23469944

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 128
Study: 21497629

Group type: EXPERIMENTAL
Intervention: DTPa
Number of subjects: 53

Group type: COMPARATOR
Intervention: dTpa
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both DTPa and dTpa
Number of subjects: 53
Study: 19968391

Group type: EXPERIMENTAL
Intervention: Best practice treatment conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study: 16518760

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) plus sulfadoxine‐pyrimethamine (SP)
Number of subjects: 2084

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ) plus sulfadoxine‐pyrimethamine (SP)
Number of subjects: 2084

Group type: EXPERIMENTAL
Intervention: Patients infected with parasites containing all 6 mutations of interest
Number of subjects: 2084
Study: 12807814

Group type: EXPERIMENTAL
Intervention: Refined quality criteria (80 general criteria and 60 specific criteria)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard review process (without refined criteria)
Number of subjects: 18
Study: 11104113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Low-dose alcohol
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: High-dose alcohol
Number of subjects: 102
Study: 9135853

Group type: EXPERIMENTAL
Intervention: Eccentric exercise (negative work, Wneg) at 25% of maximal work capacity
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Eccentric exercise (negative work, Wneg) at 50% of maximal work capacity
Number of subjects: 12

Group type: COMPARATOR
Intervention: Concentric exercise (positive work, Wpos) at 50% of maximal work capacity
Number of subjects: 12
Study: 7994447

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 111

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 3 mg
Number of subjects: 111

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 6 mg
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 2741888

Group type: EXPERIMENTAL
Intervention: High fat meal
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low fat meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GER patients
Number of subjects: 20
Study: 5394587

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide plus clidinium bromide (Librax(R))
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 31780345

Group type: EXPERIMENTAL
Intervention: Voice-hearing
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Uncontrollable thoughts
Number of subjects: 95
Study: 31220412

Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis
Number of subjects: 207

Group type: COMPARATOR
Intervention: Valacyclovir prophylaxis
Number of subjects: 207

Group type: COMPARATOR
Intervention: Preemptive therapy
Number of subjects: 207
Study: 28683833

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) for at least one continuous hour daily for 5 weeks
Number of subjects: 116

Group type: COMPARATOR
Intervention: Care-as-usual (no SSC)
Number of subjects: 116
Study: 24708192

Group type: EXPERIMENTAL
Intervention: TACE-sorafenib
Number of subjects: 91

Group type: COMPARATOR
Intervention: TACE
Number of subjects: 91
Study: 22052893

Group type: EXPERIMENTAL
Intervention: 250 milligrams of atovaquone and 100 milligrams of proguanil (250/100 milligrams) on day -7
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1000 milligrams of atovaquone and 400 milligrams of proguanil (1000/400 milligrams) on day -7
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (matching placebo for all regimens)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Atovaquone exposure during liver stage development
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Peak concentration of atovaquone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Elimination half-life of atovaquone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Postexposure prophylaxis 4 days after challenge
Number of subjects: 30
Study: 20039456

Group type: EXPERIMENTAL
Intervention: Acupuncture (once daily, starting on postoperative day 1, for up to six consecutive days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 90
Study: 18019590

Group type: EXPERIMENTAL
Intervention: Isokinetic strength measurements (Cybex Norm)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Wingate anaerobic power test
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Flexibility test, vertical jump test, grip strength test
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fat-free mass (FFM) control
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Stepwise linear regression models
Number of subjects: 44
Study: 16151830

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (three 400-kcal sessions per week at 60% of VO(2max))
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High-intensity exercise (three 400-kcal sessions per week at 80% of VO(2max))
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combined exercise groups (moderate and high-intensity)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (non-exercise)
Number of subjects: 64
Study: 11821089

Group type: EXPERIMENTAL
Intervention: Ellios pessaries (2 times 200‐mg pessary/day)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Utrogestan capsules (2 x 100‐mg capsules, two times a day)
Number of subjects: 123
Study: 10064003

Group type: COMPARATOR
Intervention: Lauric acid diet
Number of subjects: 32

Group type: COMPARATOR
Intervention: Palmitic acid diet
Number of subjects: 32
Study: 7654892

Group type: COMPARATOR
Intervention: 5-ASA
Number of subjects: 19

Group type: COMPARATOR
Intervention: 4-ASA
Number of subjects: 19
Study: 2475688

Group type: EXPERIMENTAL
Intervention: Slow-release verapamil (SR) 240 mg q.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate-release verapamil (IR) 80 mg t.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate-release verapamil (IR) 480 mg/day
Number of subjects: 0
Study: 22123

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 19

Group type: COMPARATOR
Intervention: H 87/07
Number of subjects: 19
Study: 31741279

Group type: EXPERIMENTAL
Intervention: Tablet animation format of the CHU-9D questionnaire
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Tablet image format of the CHU-9D questionnaire
Number of subjects: 438

Group type: COMPARATOR
Intervention: Text-based questionnaires
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: All formats of the CHU-9D questionnaire
Number of subjects: 438
Study: 30536575

Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing (BMI)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Information and Advice (IA)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 184

Group type: COMPARATOR
Intervention: IA
Number of subjects: 184
Study: 28377393

Group type: EXPERIMENTAL
Intervention: Behavioural intervention delivered by paediatricians or psychologists (2 consultations covering sleep hygiene and standardized behavioural strategies)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Behavioural intervention
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (no sleep training)
Number of subjects: 320
Study: 25261702

Group type: EXPERIMENTAL
Intervention: Aspirin supplementation
Number of subjects: 0
Study: 23390994

Group type: EXPERIMENTAL
Intervention: computerized CBT (cCBT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: therapist-delivered CBT (tCBT)
Number of subjects: 6
Study: 22136779

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 19193422

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg plus alfuzocin 10 mg or tamsulosin 0.2 mg daily (group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg plus alfuzocin 10 mg or tamsulosin 0.2 mg daily (group 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Withdrawal of 5ARIs (group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Withdrawal of 5ARIs (group 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cessation of 5ARIs (both groups)
Number of subjects: 120
Study: 15296472

Group type: EXPERIMENTAL
Intervention: Surgical and/or medical therapy for acromegaly
Number of subjects: 16

Group type: COMPARATOR
Intervention: No therapy (noncontrolled patients)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Baseline comparison with healthy controls
Number of subjects: 16
Study: 11025176

Group type: EXPERIMENTAL
Intervention: Antiseptic catheter (Arrow International, Reading, Pennsylvania, USA)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard triple-lumen polyurethane catheter
Number of subjects: 204
Study: 9059403

Group type: EXPERIMENTAL
Intervention: Iodixanol (13.5 g I)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Iopromide (15.0 g I)
Number of subjects: 36
Study: 8404100

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (OTB), 300 micrograms
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo, 300 micrograms
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (OTB)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 3767008

Group type: EXPERIMENTAL
Intervention: Oral ranitidine, 150 mg, with 150 ml water
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Oral ranitidine, 150 mg, with no further fluid
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo with 150 ml water
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo with no further fluid (BSP only)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ranitidine groups
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo groups
Number of subjects: 140

Group type: COMPARATOR
Intervention: BSP with placebo
Number of subjects: 140

Group type: COMPARATOR
Intervention: 150 ml water with placebo
Number of subjects: 140
Study: 30267481

Group type: EXPERIMENTAL
Intervention: Combination therapy with Surgicel and histamine‐2 receptor antagonist (H2 RA)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Monotherapy with a proton pump inhibitor (PPI)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Combination therapy with Surgicel and H2 RA
Number of subjects: 157
Study: 27727157

Group type: EXPERIMENTAL
Intervention: Single-dose maraviroc 300 mg
Number of subjects: 54
Study: 24850603

Group type: EXPERIMENTAL
Intervention: α‐lipoic acid (600 mg/day) in addition to basic therapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Basic therapy only
Number of subjects: 84
Study: 22842339

Group type: EXPERIMENTAL
Intervention: BDP/FF 100/6 μg in pressurised metered-dose inhaler (pMDI) extrafine formulation
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Salbutamol 200 μg pMDI
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: BDP/FF and Salbutamol
Number of subjects: 56
Study: 20047847

Group type: EXPERIMENTAL
Intervention: HIV-infected pregnant women
Number of subjects: 1883

Group type: COMPARATOR
Intervention: HIV-uninfected pregnant women
Number of subjects: 1883

Group type: EXPERIMENTAL
Intervention: Infants born to co-infected mothers
Number of subjects: 1883

Group type: EXPERIMENTAL
Intervention: Maternal HCV RNA
Number of subjects: 1883
Study: 18779957

Group type: EXPERIMENTAL
Intervention: PSP group
Number of subjects: 7